Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X0CB
|
|||
| Former ID |
DIB010726
|
|||
| Drug Name |
Lumacaftor
|
|||
| Synonyms |
VRT-325; VRT-422; VRT-532; VX-809
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9; ICD-9: 277] | Phase 2 | [1], [2] | |
| Company |
Vertex Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H18F2N2O5
|
|||
| Canonical SMILES |
CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O
|
|||
| InChI |
1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)
|
|||
| InChIKey |
UFSKUSARDNFIRC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 936727-05-8
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:90951
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | cAMP-dependent chloride channel (CFTR) | Target Info | Regulator | [3] |
| KEGG Pathway | ABC transporters | |||
| cAMP signaling pathway | ||||
| AMPK signaling pathway | ||||
| Gastric acid secretion | ||||
| Pancreatic secretion | ||||
| Bile secretion | ||||
| Vibrio cholerae infection | ||||
| Reactome | ABC-family proteins mediated transport | |||
| WikiPathways | ABC-family proteins mediated transport | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7481). | |||
| REF 2 | ClinicalTrials.gov (NCT00865904) Study of VX-809 in Cystic Fibrosis Subjects With the 508-CFTR Gene Mutation. U.S. National Institutes of Health. | |||
| REF 3 | A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.